Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
100estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-24 | actual | When the study began enrolling |
| Primary completion | 2025-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non-small Cell Lung Cancer
Intervention
- Biological: nivolumab + ipilimumab
Primary outcomes
what the primary-completion date above is the date OFParticipant baseline socio-demographics
measured Baseline
Participant baseline clinical characteristics
measured Baseline
Participant treatment history
measured Baseline
Treatment start and stop dates
measured Up to 6-months
Reasons for 1L treatment selection
measured Day 1
Initial 1L NIC treatment dose received
measured Day 1
Type of chemotherapy received as part of NIC treatment
measured Day 1
Participant NIC treatment chemotherapy schedule
measured Day 1
Number of NIC treatment interruptions
measured Up to 6-months
Date(s) of NIC treatment interruptions
measured Up to 6-months
Reasons for NIC treatment interruptions
measured Up to 6-months
Length of NIC treatment delay/interruption
measured Up to 6-months
Reasons for NIC treatment discontinuation
measured Up to 6-months
Type of 2L treatment received
measured Up to 6-months
Reasons for not initiating 2L treatment
measured Up to 6-months
Start and stop dates of 2L treatment initiation
measured Up to 6-months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed